#LATEST NEWSEli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialisation of potentially best-in-class, novel… Read More
#LATEST NEWSThe US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel), an autologous haematopoietic stem cell-based gene therapy. It is indicated for the treatment of paediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human… Read More
#LATEST NEWSAstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion. The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers. ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific… Read More
#LATEST NEWSDownload this In Focus report to learn about the market for antibody-based therapies and the scientific developments behind recent advances in these drugs. Read about: Where investment lies in the antibody-based drugs market Why mAbs are at the heart of phasing out animal testing The data bottleneck in AI antibody… Read More
#LATEST NEWSThe US Food and Drug Administration (FDA) has granted accelerated approval for Avlayah (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier. Avlayah is an enzyme replacement therapy indicated for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS… Read More
25 March 2026 · Diana Turner
24 March 2026 · Diana Turner
18 March 2026 · Diana Turner
24 March 2026 · Reece Armstrong
18 March 2026 · Bruno Quinney
17 March 2026 · Bruno Quinney
